IP Library Granted Patent US 12674797
Granted Patent B2
US 12674797 · App. 17/762,210 · Granted Jul 7, 2026

Method for measuring nucleic acid content in lipid nanoparticles using ultraviolet spectrometry

Inventors: Lee J. Klein (Collegeville, PA); Leia C. Epstein (Norristown, PA)
Assignee: Merck Sharp & Dohme LLC
G01N33/52A61K9/1271G01N21/33
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12674797
App. No.
17/762,210
Filed
Mar 21, 2022
Granted
Jul 7, 2026
Kind
B2
Art Unit
1758
USPC
436/94
Abstract

An ultraviolet (UV) absorbance assay for measuring the concentration of large RNA molecules such as mRNA in suspensions comprising RNA-lipid nanoparticles (RNA-LNPs) is described.

Claims (183)

1 . A method for measuring the ribonucleic acid (RNA) concentration of a suspension of RNA-lipid nanoparticle (RNA-LNPs) wherein the RNA-LNPs comprise ionizable cationic lipids and the RNA is at least 100 nucleotides in length, the method comprising:

(a) mixing a suspension of RNA-LNPs comprising ionizable cationic lipids and RNA at least 100 nucleotides in length with an assay diluent comprising (i) a surfactant that disrupts the RNA-LNPs into their RNA and LNP components and is optically transparent at λ max of the RNA and (ii) an alkylamine that denatures the RNA by providing a pH of at least pH 11 or about pH 12, displaces the ionizable cationic lipids of the LNP that are associated with or complexed to the denatured RNA, and is optically transparent at λ max of the RNA, to provide a diluted sample solution;

(b) measuring absorbance of the diluted sample solution at lambda maximum of the RNA (λ max ) to provide a Net Absorbance or measuring absorbance of the diluted sample solution at λ max and at 400 nm and subtracting the absorbance at 400 nm from the absorbance at λ max to provide an adjusted Net Absorbance; and

(c) using the Net Absorbance or the adjusted Net Absorbance to determine the RNA concentration in the suspension of the RNA-LNPs.

2 . The method of claim 1 , wherein the alkylamine comprises a tertiary amine of the formula NRR′R″ wherein R, R′, and R″ are each independently a C1 to C18 alkyl.

3 . The method of claim 1 , wherein the alkylamine is selected from the group consisting of N,N-dimethylbutylamine (DMBA; CAS 927-62-8), N,N-diethylethanamine (TEA; CAS 121-44-8), N,N-diisopropylethylamine (DIPEA; CAS 7087-68-5), and hexan-1-amine (1-HA; CAS 111-26-2).

4 . The method of claim 1 , wherein the surfactant is selected from the group consisting of sodium dodecyl sulfate (SDS; CAS 151-21-3), cetyltrimethylammonium bromide (C-TAB; CAS 57-09-0), and polyethylene glycol alkyl ether (BRIJ).

5 . The method of claim 1 , wherein the surfactant is sodium dodecyl sulfate (SDS) and the alkylamine is N,N-dimethylbutylamine (DMBA) or the surfactant is a polyethylene glycol alkyl ether and the alkylamine is hexan-1-amine (1-HA).

6 . The method of claim 1 , wherein the ionizable cationic lipids comprise a tertiary amine.

7 . The method of claim 6 , wherein the ionizable cationic lipid comprises a tertiary amine and at least one saturated or unsaturated hydrocarbon chain comprising at least nine carbon atoms.

8 . The method of claim 1 , wherein the ionizable cationic lipid is dilinoleylmethyl-4-dimethylaminobutyrate (D-Lin-MC3-DMA; CAS 1224606-06-7).

9 . The method of claim 1 , wherein the assay diluent further includes a metal chelator.

10 . The method of claim 1 , wherein the assay diluent comprises about 750 mM N,N-dimethylbutylamine, about 10% (w/v) SDS, and about 1 mM EDTA.

11 . The method of claim 1 , wherein the RNA concentration is determined using the formula

mRNA

(

mg

mL

)

=

(

Net

Absorbance

or

adjusted

Net

Absorbance

path

length

(

cm

)

)

×

(

40

μg

·

cm

mL

)

×

(

1

mg

mL

1000

μg

mL

)

×

Dilution

Factor

wherein

Dilution

Factor

=

Diluted

Sample

Solution

volume

(

μL

)

Initial

Sample

Suspension

volume

(

μL

)

.

12 . A method for measuring the ribonucleic acid (RNA) concentration of a suspension of RNA-lipid nanoparticle (RNA-LNPs), the method comprising:

(a) providing a predetermined volume of a sample suspension comprising RNA-LNPs wherein the RNA-LNPs comprise ionizable cationic lipids and the RNA is at least 100 nucleotides in length;

(b) mixing the sample suspension of RNA-LNPs with a predetermined volume of an assay diluent comprising (i) a surfactant that disrupts the RNA-LNPs into their RNA and LNP components and is optically transparent at λ max of the RNA and (ii) an alkylamine that denatures the RNA at a pH of at least pH 11 or about pH 12, displaces the ionizable cationic lipids of the LNP that are associated with or complexed to the denatured RNA, and is optically transparent at λ max of the RNA, to provide a diluted sample solution in which the RNA is denatured and dissociated from the ionizable cationic lipids;

(c) measuring absorbance of the diluted sample solution at lambda maximum of the RNA (λ max ) in the diluted sample solution to provide a Net Absorbance or measuring absorbance of the diluted sample solution at λ max and at 400 nm and subtracting the absorbance at 400 nm from the absorbance at λ max to provide an adjusted Net Absorbance; and

(d) using the Net Absorbance or the adjusted Net Absorbance and the formula

mRNA

(

mg

mL

)

=

(

Net

Absorbance

or

adjusted

Net

Absorbance

path

length

(

cm

)

)

×

(

40

μg

·

cm

mL

)

×

(

1

mg

mL

1000

μg

mL

)

×

Dilution

Factor

wherein

Dilution

Factor

=

Diluted

Sample

Solution

volume

(

μL

)

Initial

Sample

Suspension

volume

(

μL

)

 to determine the RNA concentration in the suspension of the RNA-LNPs.

13 . The method of claim 12 , wherein the alkylamine comprises a tertiary amine of the formula NRR′R″ wherein R, R′, and R″ are each independently a C1 to C18 alkyl.

14 . The method of claim 12 , wherein the surfactant is SDS and the alkylamine is N,N-dimethylbutylamine (DMBA) or the surfactant is a polyethylene glycol alkyl ether and the alkylamine is hexan-1-amine (1-HA).

15 . The method of claim 12 , wherein the ionizable cationic lipids comprise a tertiary amine.

16 . The method of claim 15 , wherein the ionizable cationic lipid comprises a tertiary amine and at least one saturated or unsaturated hydrocarbon chain comprising at least nine carbon atoms.

17 . The method of claim 12 , wherein the ionizable cationic lipid is dilinoleylmethyl-4-dimethylaminobutyrate (D-Lin-MC3-DMA; CAS 1224606-06-7).

18 . The method of claim 12 , wherein the assay diluent further includes a metal chelator.

19 . The method of claim 18 , wherein the metal chelator is ethylenediaminetetraacetic acid (EDTA).

20 . The method of claim 12 , wherein the assay diluent comprises about 750 mM N,N-dimethylbutylamine, about 10% (w/v) SDS, and about 1 mM EDTA.